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Abstract
We have learned much about the short-term sequelae of congenital Zika virus (ZIKV) infection 
since the Centers for Disease Control and Prevention activated its ZIKV emergency response in 
January 2016. Nevertheless, gaps remain in our understanding of the full spectrum of adverse 
health outcomes related to congenital ZIKV infection and how to optimize health in those who are 
affected. To address the remaining knowledge gaps, support affected children so they can reach 
their full potential, and make the best use of available resources, a carefully planned public health 
approach in partnership with pediatric health care providers is needed. An essential step is to use 
population-based data captured through surveillance systems to describe congenital Zika 
syndrome. Another key step is using collected data to investigate why some children exhibit 
certain sequelae during infancy and beyond, whereas others do not, and to describe the clustering 
of anomalies and the timing of when these anomalies occur, among other research questions. The 
final critical step in the public health framework for congenital Zika syndrome is an intervention 
strategy with evidence-based best practices for longer-term monitoring and care. Adherence to 
recommended evaluation and management procedures for infants with possible congenital ZIKV 
infection, including for those with less obvious developmental and medical needs at birth, is 
essential. It will take many years to fully understand the effects of ZIKV on those who are 
congenitally infected; however, the lifetime medical and educational costs as well as the emotional 
impact on affected children and families are likely to be substantial.
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The US Centers for Disease Control and Prevention (CDC) activated its Emergency 
Operations Center in January 2016 for the Zika virus (ZIKV) response. In many ways, the 
Zika epidemic and resulting response have been unprecedented, marking the first time that 
an arbovirus has been shown to cause birth defects and the first time in more than a half-
century that a viral disease caused a birth defect epidemic.1 The response soon escalated to 
become the most complex outbreak response in the CDC’s history. The effort required 
contributions from across the agency as well as routine collaboration with state and global 
public health partners with both infectious and noninfectious disease expertise.
ZIKV primarily spreads through the bite of an infected Aedes mosquito (Aedes aegypti and 
Aedes albopictus); it can also be transmitted from mother to fetus during pregnancy or 
between sexual partners even if the infected partner is asymptomatic.2 Evidence of 
transmission is also found through blood transfusions as well as laboratory exposure.3 ZIKV 
has spread to >60 countries and territories, including Puerto Rico.4 In addition to travel-
associated Zika cases in US residents, local mosquito-borne ZIKV transmission has also 
been reported in Florida and Texas.5
Although the presence of microcephaly first signaled the link between ZIKV infection 
during pregnancy and poor birth outcomes, other congenital anomalies may also be of 
concern; moreover, some affected infants do not have microcephaly. Congenital Zika 
syndrome (CZS) has been described as a recognizable pattern of congenital anomalies 
associated with ZIKV infection during pregnancy that is characterized by severe 
microcephaly with a partially collapsed skull; thin cerebral cortices with subcortical 
calcifications; eye anomalies, including macular scarring and focal pigmentary retinal 
mottling; congenital contractures or a limited range of joint motion; marked hypertonia; and 
symptoms of extrapyramidal involvement.6 Additionally, infants with a head circumference 
in the normal range at birth can have brain abnormalities that are consistent with CZS and 
the postnatal development of microcephaly.7
To date, estimates of health care and familial costs associated with the Zika epidemic have 
been limited to microcephaly as the primary phenotype. Li et al8 estimated the total lifetime 
cost for a surviving infant with Zika-associated microcephaly to be $3.8 million with the 
potential to reach $10 million for those who survive to adulthood. Therefore, the lifetime 
medical and educational costs as well as the emotional impact for children and families 
affected by the Zika epidemic (including the impact beyond microcephaly) are likely to be 
substantial.
In November 2016, the World Health Organization Emergency Committee recommended 
that the global Zika response transition to a longer-term approach with dedicated, sustained 
resources.9 By September 2017, the CDC transitioned its Zika emergency response activities 
to existing programs but noted that ZIKV continues to be a public health threat in the United 
States and internationally. Moving forward, broadening the public health approach beyond 
the immediate needs of pregnant women, fetuses, and infants to examine long-term child 
outcomes is needed. Many questions remain about the future of surviving children who are 
affected by CZS as they transition from infancy to childhood. The optimal way to address 
the remaining knowledge gaps, support affected children so they can reach their full 
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potential, and make the best use of available resources is through a carefully planned and 
coordinated public health approach in partnership with pediatric health care providers.
PUBLIC HEALTH APPROACH
In general, the public health approach is operationalized as a cycle that includes 
surveillance, research, and intervention (see Fig 1 for a public health approach to CZS). 
Since January 2016, the CDC, in collaboration with other public health partners, has 
conducted rapid surveillance on Zika-affected pregnant women and used findings to plan for 
services and update recommendations for care, including clinical guidance for health care 
providers who care for pregnant women and infants. Continued surveillance of affected 
children beyond birth will allow public health agencies to refine guidance and develop best 
practices for longer-term monitoring and care.
Surveillance Objectives
An essential step in the public health approach is to use population-based data captured 
through surveillance systems to describe the problem. Surveillance of CZS is needed to 
answer several key questions. How many pregnant women are infected with ZIKV? How 
often do Zika-affected pregnancies result in adverse outcomes, and what are those adverse 
outcomes (eg, pregnancy loss, birth defects, and/or developmental disabilities)? What is the 
risk for preterm birth or fetal growth restriction? How do adverse pregnancy outcomes (or 
the frequency of occurrence) differ by the gestational timing of prenatal infection? What are 
the medical and developmental manifestations of congenital Zika infection,6 and how do the 
manifestations differ from other intrauterine infections (eg, congenital rubella virus or 
cytomegalovirus infection)?
Surveillance Efforts in the United States and US Territories
In February 2016, ZIKV and congenital ZIKV infections became nationally notifiable 
conditions in the United States, prompting health care providers to report laboratory-
confirmed and symptomatic cases of ZIKV to their local, state, tribal, or territorial health 
departments and to collect clinical and follow-up information.10
US Zika Pregnancy and Infant Registry—In February 2016, in collaboration with 
local, state, tribal, and territorial health departments, the CDC established the US Zika 
Pregnancy and Infant Registry (USZPIR) to track women with laboratory evidence of ZIKV 
infection during pregnancy and collect data on pregnancy and infant outcomes in those 
pregnancies. All US states, the District of Columbia, and all US territories are collaborating 
in the USZPIR, which includes the US Zika Pregnancy Registry and the Puerto Rico Zika 
Active Pregnancy Surveillance System. The goal of the USZPIR is to better understand the 
effects of ZIKV infection during pregnancy, including the effects of timing and clinical 
presentation of infection, risk, and the spectrum of outcomes associated with maternal ZIKV 
infection. In addition, data collected from the USZPIR have provided initial estimates of the 
proportion of pregnancies affected by birth defects that are potentially associated with 
congenital Zika infection, which are 5% to 10% overall11,12 and 8% to 15% for those with 
first-trimester exposure.12,13
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The USZPIR collects data during pregnancy and delivery, throughout infancy, and up to 24 
months in the US states and most territories and 36 months in Puerto Rico. Women and 
children are monitored by using medical record abstraction of prenatal, emergency 
department, delivery and/or birth, and pediatric follow-up records. Pregnancy and delivery 
data are comprehensive and include (but are not limited to) ZIKV exposure, symptoms, and 
test results; pregnancy complications; and prenatal imaging findings. Neonatal assessment 
and infant and child follow-up data are derived from test results, physical examinations, 
growth and developmental assessments, neonatal neuroimaging, ophthalmologic 
examinations, hearing evaluations, and other consultations. Data about survival and the 
presence of birth defects also are collected. Knowledge gained from the USZPIR can lead to 
improved clinical guidance and facilitate planning for health services for affected children 
and their families. In Puerto Rico and some other US jurisdictions, all infants who are born 
to women with evidence of possible ZIKV infection during pregnancy are referred to the 
Children with Special Health Care Needs Program for close follow-up, monitoring, and 
needed services.14 Continued support from clinicians who provide health care to pregnant 
women and their infants is critical to the ability of these surveillance programs to provide 
quality data to address many unanswered questions.
Zika Birth Defects Surveillance—The CDC guidance is for health care providers to 
screen all pregnant women for ZIKV exposure before and during pregnancy at every 
prenatal care visit. However, because ZIKV infections are almost always asymptomatic or 
mild,15 health care providers might miss the opportunity to ask patients about exposure and 
make decisions about testing for ZIKV infection per CDC recommendations. Consequently, 
numerous potential cases of prenatal exposure or infection might not be documented in the 
USZPIR. To identify cases of congenital ZIKV infection and birth defects that are 
potentially related to ZIKV infection and might be missed by the registry, the CDC 
established a population-based monitoring program: the Zika Birth Defects Surveillance 
system. Birth defect cases that are potentially related to ZIKV are systematically captured 
within defined catchment areas in the US states and territories with possible endemic 
transmission (ie, areas with an observed distribution of Aedes mosquitoes) or areas that are 
associated with a high volume of travel from endemic countries. Standard case definitions 
for possible Zika-related birth defects for the Zika Birth Defects Surveillance system and 
those that are monitored in the USZPIR ensure consistency across surveillance systems. The 
information collected will be used to understand the impact of these conditions on 
communities, develop population-level prevention strategies, and assist with medical and 
social services referrals for affected individuals and families; the data can also be used to 
assess the health and developmental outcomes of these children. This marks the first time 
that pregnancy surveillance and birth defect surveillance activities have combined their 
efforts to address a common goal.16 Moving forward, this combined infrastructure could 
serve as a model for addressing myriad public health problems that affect maternal and child 
health.
Research Objectives
Another key step in the public health approach to CZS is using the data to investigate why 
some children exhibit certain sequelae during infancy and beyond, whereas others do not. 
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This knowledge can be used to inform clinical practice and interventions. An important 
future priority of the overall Zika response is to expand our understanding of the long-term 
outcomes of congenitally infected infants.17 Research gaps include a lack of knowledge 
about long-term developmental, sensory, and motor functioning and medical outcomes, as 
well as effective interventions; limited data on the potential for late-onset hearing loss, 
developmental delay, or severe neurologic problems as sequelae in congenitally infected 
infants with no detectable adverse outcomes at birth7; and survival. Extensive monitoring 
may be necessary for many years until a safe and effective vaccine is made available and 
widely used.
Ongoing and Planned Research Studies
The CDC is collaborating with partners to identify the full spectrum of CZS by monitoring 
affected infants during childhood. Several pregnancy cohort studies are being conducted 
around the world in Zika-affected countries. One cohort study is the Zika en Embarazadas y 
Niños en Colombia, a partnership between the CDC and Colombia’s national public health 
institute.18 This study will enroll up to 5000 pregnant women, their partners, and their 
infants (all regardless of Zika exposure) in several cities in Colombia with regular follow-up 
through pregnancy and until the infants are 6 months old. A subset of children, along with a 
parent or legal guardian, will be followed until the child is about four years of age. In 
addition, the US National Institutes of Health–funded Zika in Infants and Pregnancy study 
aims to enroll as many as 10000 pregnant women (with and without Zika infection) at up to 
15 sites.19 These and other studies will help increase knowledge about the full spectrum of 
effects of prenatal ZIKV infection and other factors (eg, environment, previous infections, 
and nutrition) that might play a role in increasing the risk for adverse outcomes after 
exposure to ZIKV infection.
Studies to increase knowledge about the fetal and infant effects of ZIKV infection during 
pregnancy will require input from a broad range of experts, including obstetricians, 
maternal–fetal medicine specialists, pediatricians and pediatric subspecialists, and 
epidemiologists to lead data analyses and interpretation. These experts will need to work 
collaboratively to address the primary questions posed by the global Zika response.
Insights into the longer-term consequences of CZS are starting to surface. A recent study 
showed that after congenital infection, ZIKV can continue to replicate in infants’ brain tissue 
after birth.20 In addition, researchers of a Brazilian case series described 13 infants with 
brain anomalies and laboratory evidence of congenital ZIKV infection and normal head size 
at birth.7 On follow-up, all had a decrease in the rate of head circumference growth, with 
postnatal microcephaly diagnosed in 11 of the 13 infants by the end of their first year. This 
case series illustrated that microcephaly at birth is not a necessary feature of the syndrome 
but can be seen later in infancy. A second study in 2017 reported eye findings in infants 
without microcephaly or other brain anomalies who were born to mothers with laboratory 
evidence of ZIKV infection.21 These findings have important implications for infants who 
are born without visible evidence of congenital Zika infection. Information is lacking to 
better characterize the complete phenotype of CZS, describe the clustering of anomalies, and 
define the timing of when these anomalies occur.
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The long-term effects of this emerging infection are difficult to predict; however, parallels 
can be drawn to other congenital viral infections. For example, hearing loss because of 
congenital cytomegalovirus infection can sometimes develop during the first year of life 
even when it is absent at birth.22 As another example, rubella virus infection in utero is 
associated with autism (presenting in early childhood) and adult-onset diabetes.23,24 
However, ZIKV infection has a unique natural history that continues to unfold in new and 
challenging ways. It will take many years to fully understand the effects of ZIKV on the 
fetus and congenitally infected infant. This is, in part, because some conditions might be 
absent or difficult to detect at birth; in addition, we do not have enough cases of congenital 
infection in infants compiled to sufficiently power epidemiologic studies on the long-term 
consequences of ZIKV infection during pregnancy.
Intervention Objectives
The final critical element in a public health approach to CZS is an intervention strategy with 
evidence-based best practices. An effective Zika strategy would determine which 
examinations and evaluations should be performed at what intervals; it would continue to 
assess practices such as when and how to intervene to improve outcomes and how to best 
coordinate care, including when to refer patients to other professionals.
Best Practices for Obstetric and Maternal-Fetal Care
Public health surveillance, research studies, and the development of evidence-based 
interventions for CZS will inform obstetric health care practices and improve counseling for 
Zika-exposed pregnant women and their families. Currently, counseling pregnant women 
with possible ZIKV infection is challenging because the long-term outcomes among 
children who are born to women with ZIKV infection during pregnancy are largely 
unknown. Obstetric health care providers should be prepared to counsel pregnant women 
with exposure to ZIKV regarding what to expect for child outcomes,25 including the 
spectrum of birth defects and other outcomes that are associated with prenatal ZIKV 
infection, levels of risk, and effects of the timing of infection and other cofactors. 
Counseling pregnant women in the setting of medical uncertainty regarding child outcomes 
is not unique to ZIKV infection.26 Other congenital infections have a wide range of 
presentations and varying long-term outcomes. To the extent possible, pregnant women with 
exposure to ZIKV should be informed of the potential fetal risks, availability and limitations 
of diagnostic testing and monitoring during pregnancy, and recommended services for 
infants who are born to mothers with ZIKV exposure during pregnancy. The CDC has 
developed interim guidance in the form of an obstetrics clinical tool kit to assist health care 
providers who serve pregnant women who are exposed to ZIKV.27,28 As new information 
becomes available, these guidelines will be updated accordingly. Additionally, Zika Care 
Connect (ZCC) is a resource for pregnant women who seek clinical services in accordance 
with the CDC’s interim guidance. ZCC establishes a network of specialty providers, 
including those in maternal–fetal medicine and obstetrics and/or gynecology, who are 
dedicated to the care of families affected by ZIKV.29
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Best Practices for Pediatric and Interdisciplinary care
Partnerships between pediatric health care providers and public health professionals are 
essential to ensuring appropriate care for those who are affected by CZS. A recent CDC 
report highlighted gaps in evaluating and managing infants with possible congenital ZIKV 
infection.13 Initial USZPIR data showed that most infants with possible congenital ZIKV 
infection (ie, those who are born to women with [possible or confirmed] laboratory evidence 
of ZIKV infection) are not receiving CDC-recommended postnatal neuroimaging or ZIKV 
testing at birth.13,30 Adherence to recommended evaluation and management procedures for 
infants with possible congenital ZIKV infection is essential to characterize the full spectrum 
of CZS. The CDC has produced a pocket guide summarizing pediatric guidance on initial 
evaluation and outpatient management.31 Continued monitoring and follow-up with careful 
physical examinations and developmental evaluations beyond infancy will help elucidate the 
wide range of possible sequelae of congenital Zika infection.32
To inform the pediatric response to CZS, it will be critical to engage experts from countries 
that have greater experience with children affected by Zika. Communities in Brazil were 
affected earliest in the global spread of ZIKV and now have affected children entering their 
third year of life. Partnering with experts in Brazil to better characterize the medical and 
habilitative needs of children who were congenitally affected remains critical. The CDC is 
collaborating with the Brazilian Ministry of Health, the Secretariat of Health, and local 
clinicians on several investigations to evaluate children beyond infancy. One collaboration is 
a systematic assessment of the developmental and physical health of young children with 
CZS at ~12 to 24 months of age in several northeastern states of Brazil. Follow-up 
information from affected infants is key to understanding what services and support systems 
will be most beneficial to families that are caring for such children.
Developmentally oriented, interdisciplinary care33 will be essential for the success and well-
being of children who are affected by Zika and their families. Consultation with pediatric 
specialists, such as neurologists, developmental pediatricians, and gastroenterologists, is 
important to optimize health during infancy and childhood. As a child grows, developmental 
care and educational needs will grow, and services from occupational, speech and/or 
language, and other specialists may be needed. Issues that might affect a child’s health and 
development also include vision impairment or hearing loss. Although traditional 
interventions, such as glasses or hearing aids, might be used to optimize vision and hearing, 
vision and speech therapy will still be necessary for development. In addition, early 
intervention educators and physical therapists will be needed to optimize impaired motor 
and cognitive functioning. Families will likely need to access birth–to–3-years-old early-
intervention programs34 for such integrated care; as the children grow, they will need access 
to early-childhood special education programs.35 The coordination of early-intervention 
services with medical services will be best accomplished through a child’s medical home.36 
Therefore, having an informed primary health care provider will be essential for optimal, 
coordinated, and ongoing care. ZCC can also help families that are affected by ZIKV and 
their primary health care providers identify local specialized pediatric care and ensure long-
term follow-up.29 Families will likely need much support, and family support organizations, 
such as Family Voices and Family-to-Family Health Information Centers,37 can help. These 
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and other resources for health care providers who serve children who are affected by ZIKV 
are compiled on the CDC’s Web site.38
Some children with congenital Zika infection may have less obvious developmental and 
medical needs at birth, but it remains crucial to monitor their health and development. 
Monitoring growth and developmental milestones at each well-child visit is consistent with 
current well-child care guidelines.39 In addition, parents should receive information on 
monitoring development so that concerns are recognized and appropriate interventions are 
initiated in a timely manner. The CDC’s “Learn the Signs. Act Early” program teaches 
parents about typical and atypical development.40
CONCLUSIONS
We have learned much about the short-term sequelae of congenital ZIKV infection since the 
CDC activated its ZIKV emergency response in January 2016. Nevertheless, gaps remain in 
our understanding of the full spectrum of adverse health outcomes related to congenital 
ZIKV infection and how to optimize health in those who are affected. A carefully planned 
public health approach must include input from and partnerships among experts in multiple 
clinical and public health disciplines to improve the ability to anticipate needs, provide 
appropriate care for those who are affected, and ensure that patients reach their full potential. 
The emergent nature of congenital Zika infection has required an all-hands-on-deck 
approach to maximize the effectiveness of our public health actions. To advance health care 
and promote well-being in families and children who are impacted by Zika, this work must 
continue intensively, and collaboration across sectors must be ensured.
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FIGURE 1. 
Framework for a public health approach to CZS.
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